Bonness Enterprises Inc. continued to hold its position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 83,608 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Pfizer accounts for 2.4% of Bonness Enterprises Inc.’s portfolio, making the stock its 12th largest position. Bonness Enterprises Inc.’s holdings in Pfizer were worth $2,699,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Jennison Associates increased its stake in Pfizer by 108.2% in the third quarter. Jennison Associates now owns 9,550,121 shares of the biopharmaceutical company’s stock valued at $299,969,000 after buying an additional 4,963,367 shares during the period. Eagle Asset Management increased its stake in Pfizer by 100.3% in the third quarter. Eagle Asset Management now owns 7,570,014 shares of the biopharmaceutical company’s stock valued at $237,774,000 after buying an additional 3,791,218 shares during the period. Janus Capital Management increased its stake in Pfizer by 35.2% in the third quarter. Janus Capital Management now owns 11,561,514 shares of the biopharmaceutical company’s stock valued at $363,157,000 after buying an additional 3,012,704 shares during the period. Verde Servico Internacionais acquired a new stake in Pfizer during the fourth quarter valued at approximately $24,213,000. Finally, Boston Advisors increased its stake in Pfizer by 315.2% in the fourth quarter. Boston Advisors now owns 617,222 shares of the biopharmaceutical company’s stock valued at $19,924,000 after buying an additional 468,580 shares during the period.

Shares of Pfizer Inc. (NYSE:PFE) opened at 30.52 on Thursday. The firm has a market capitalization of $188.40 billion and a PE ratio of 22.91. The company has a 50-day moving average of $31.68 and a 200-day moving average of $33.16. Pfizer Inc. has a 52 week low of $28.47 and a 52 week high of $36.46.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 27th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.09. The business earned $12.10 billion during the quarter, compared to analyst estimates of $11.56 billion. The business’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.57 EPS. On average, equities analysts forecast that Pfizer Inc. will post $2.18 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 2nd. Shareholders of record on Friday, February 5th will be issued a $0.30 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.24. This represents a $1.20 dividend on an annualized basis and a yield of 3.93%. The ex-dividend date of this dividend is Wednesday, February 3rd.

Several analysts recently commented on the stock. Argus upped their price target on shares of Pfizer from $41.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, November 3rd. Atlantic Securities set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, December 24th. Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $35.00 to $38.00 in a research report on Friday, October 2nd. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Monday, January 18th. Finally, Independent Research GmbH restated a “neutral” rating and set a $35.00 price objective on shares of Pfizer in a research report on Friday, October 2nd. Six analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $39.83.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.